Hawre J Jalal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6331300/publications.pdf Version: 2024-02-01



HANNDELLALAL

#	Article	IF	CITATIONS
1	Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science, 2018, 361, .	6.0	416
2	Network Meta-analysis of Margin Threshold for Women With Ductal Carcinoma In Situ. Journal of the National Cancer Institute, 2012, 104, 507-516.	3.0	117
3	Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. Medical Decision Making, 2018, 38, 400-422.	1.2	85
4	An Overview of R in Health Decision Sciences. Medical Decision Making, 2017, 37, 735-746.	1.2	73
5	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. Value in Health, 2020, 23, 734-742.	0.1	51
6	Forecasting trends in disability in a super-aging society: Adapting the Future Elderly Model to Japan. Journal of the Economics of Ageing, 2016, 8, 42-51.	0.6	48
7	Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. Medical Decision Making, 2015, 35, 584-595.	1.2	43
8	Linear Regression Metamodeling as a Tool to Summarize and Present Simulation Model Results. Medical Decision Making, 2013, 33, 880-890.	1.2	40
9	Age and generational patterns of overdose death risk from opioids and other drugs. Nature Medicine, 2020, 26, 699-704.	15.2	37
10	A Gaussian Approximation Approach for Value of Information Analysis. Medical Decision Making, 2018, 38, 174-188.	1.2	36
11	Carfentanil and the rise and fall of overdose deaths in the United States. Addiction, 2021, 116, 1593-1599.	1.7	35
12	Computing PROPr Utility Scores for PROMIS® Profile Instruments. Value in Health, 2020, 23, 370-378.	0.1	33
13	A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling. Pharmacoeconomics, 2019, 37, 1329-1339.	1.7	28
14	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. Medical Decision Making, 2020, 40, 314-326.	1.2	28
15	Costâ€Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 1751-1757.	1.5	27
16	"Time Traveling Is Just Too Dangerous―but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Value in Health, 2019, 22, 611-618.	0.1	22
17	Some Health States Are Better Than Others. Medical Decision Making, 2016, 36, 927-940.	1.2	18
18	Estimating the Impact of Low Influenza Activity in 2020 on Population Immunity and Future Influenza Seasons in the United States. Open Forum Infectious Diseases, 2022, 9, ofab607.	0.4	17

Hawre J Jalal

#	Article	IF	CITATIONS
19	Data Needs in Opioid Systems Modeling: Challenges and Future Directions. American Journal of Preventive Medicine, 2021, 60, e95-e105.	1.6	15
20	Hexamaps for Age–Period–Cohort Data Visualization and Implementation in R. Epidemiology, 2020, 31, e47-e49.	1.2	11
21	Costâ€Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease. Journal of the American Heart Association, 2015, 4, .	1.6	10
22	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharmacoeconomics, 2017, 35, 1073-1085.	1.7	9
23	BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling. Frontiers in Physiology, 2021, 12, 662314.	1.3	8
24	An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. Medical Decision Making, 2023, 43, 3-20.	1.2	8
25	The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. Pharmacoeconomics, 2019, 37, 871-877.	1.7	6
26	Future projection of the health and functional status of older people in Japan: A multistate transition microsimulation model with repeated crossâ€sectional data. Health Economics (United Kingdom), 2021, 30, 30-51.	0.8	6
27	Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. MDM Policy and Practice, 2020, 5, 238146832093289.	0.5	6
28	A Multidimensional Array Representation of State-Transition Model Dynamics. Medical Decision Making, 2020, 40, 242-248.	1.2	6
29	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. International Journal of Drug Policy, 2021, 88, 102726.	1.6	5
30	Exponential growth of drug overdose poisoning and opportunities for intervention. Addiction, 2022, 117, 1200-1202.	1.7	5
31	Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. Medical Decision Making, 2020, 40, 718-721.	1.2	4
32	Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. Value in Health, 2020, 23, 1534-1542.	0.1	3
33	Associations Between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes. Pain Medicine, 2020, 21, 1871-1890.	0.9	2
34	Microsimulation Model to Compare Enteral and Parenteral Iron Supplementation in Children With Intestinal Failure. Journal of Parenteral and Enteral Nutrition, 2021, 45, 810-817.	1.3	2
35	Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations. Pharmacoeconomics, 2011, 29, 173-174.	1.7	1
36	ls further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis. Vaccine, 2021, 39, 3608-3613.	1.7	1

#	Article	IF	CITATIONS
37	Reply commentary by Jalal and Burke. International Journal of Drug Policy, 2022, , 103674.	1.6	1
38	APCtools: Descriptive and Model-based Age-Period-Cohort Analysis. Journal of Open Source Software, 2022, 7, 4056.	2.0	1